PT - JOURNAL ARTICLE AU - Edward Burn AU - Seng Chan You AU - Anthony G. Sena AU - Kristin Kostka AU - Hamed Abedtash AU - Maria Tereza F. Abrahão AU - Amanda Alberga AU - Heba Alghoul AU - Osaid Alser AU - Thamir M Alshammari AU - Carlos Areia AU - Juan M. Banda AU - Jaehyeong Cho AU - Aedin C Culhane AU - Alexander Davydov AU - Frank J DeFalco AU - Talita Duarte-Salles AU - Scott DuVall AU - Thomas Falconer AU - Weihua Gao AU - Asieh Golozar AU - Jill Hardin AU - George Hripcsak AU - Vojtech Huser AU - Hokyun Jeon AU - Yonghua Jing AU - Chi Young Jung AU - Benjamin Skov Kaas-Hansen AU - Denys Kaduk AU - Seamus Kent AU - Yeesuk Kim AU - Spyros Kolovos AU - Jennifer C.E. Lane AU - Hyejin Lee AU - Kristine E Lynch AU - Rupa Makadia AU - Michael E. Matheny AU - Paras Mehta AU - Daniel R Morales AU - Karthik Natarajan AU - Fredrik Nyberg AU - Anna Ostropolets AU - Rae Woong Park AU - Jimyung Park AU - Jose D. Posada AU - Albert Prats-Uribe AU - Gowtham Rao AU - Christian Reich AU - Yeunsook Rho AU - Peter Rijnbeek AU - Selva Muthu Kumaran Sathappan AU - Lisa M. Schilling AU - Martijn Schuemie AU - Nigam H. Shah AU - Azza Shoaibi AU - Seokyoung Song AU - Matthew Spotnitz AU - Marc A. Suchard AU - Joel N. Swerdel AU - David Vizcaya AU - Salvatore Volpe AU - Haini Wen AU - Andrew E. Williams AU - Belay B. Yimer AU - Lin Zhang AU - Oleg Zhuk AU - Daniel Prieto-Alhambra AU - Patrick Ryan TI - An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza AID - 10.1101/2020.04.22.20074336 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.22.20074336 4099 - http://medrxiv.org/content/early/2020/04/25/2020.04.22.20074336.short 4100 - http://medrxiv.org/content/early/2020/04/25/2020.04.22.20074336.full AB - Background To better understand the profile of individuals with severe coronavirus disease 2019 (COVID-19), we characterised individuals hospitalised with COVID-19 and compared them to individuals previously hospitalised with influenza.Methods We report the characteristics (demographics, prior conditions and medication use) of patients hospitalised with COVID-19 between December 2019 and April 2020 in the US (Columbia University Irving Medical Center [CUIMC], STAnford Medicine Research data Repository [STARR-OMOP], and the Department of Veterans Affairs [VA OMOP]) and Health Insurance Review & Assessment [HIRA] of South Korea. Patients hospitalised with COVID-19 were compared with patients previously hospitalised with influenza in 2014-19.Results 6,806 (US: 1,634, South Korea: 5,172) individuals hospitalised with COVID-19 were included. Patients in the US were majority male (VA OMOP: 94%, STARR-OMOP: 57%, CUIMC: 52%), but were majority female in HIRA (56%). Age profiles varied across data sources. Prevalence of asthma ranged from 7% to 14%, diabetes from 18% to 43%, and hypertensive disorder from 22% to 70% across data sources, while between 9% and 39% were taking drugs acting on the renin-angiotensin system in the 30 days prior to their hospitalisation. Compared to 52,422 individuals hospitalised with influenza, patients admitted with COVID-19 were more likely male, younger, and, in the US, had fewer comorbidities and lower medication use.Conclusions Rates of comorbidities and medication use are high among individuals hospitalised with COVID-19. However, COVID-19 patients are more likely to be male and appear to be younger and, in the US, generally healthier than those typically admitted with influenza.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form, with the following declarations made: DPA reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. DV reports personal fees from Bayer, outside the submitted work; and he is a full-time employee at a pharmaceutical company. DM reports funding support from the Wellcome Trust, NIHR, Scottish CSO and Tenovus Scotland for research unrelated to this work. SCY reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. AG reports personal fees from Regeneron Pharmaceuticals, outside the submitted work; and she a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. YJ reports employee of AbbVie and own company stock. AA reports: I am currently employed at Alberta Health Services (AHS) as a Data Science Lead redeployed as an epidemiologist to aid in the COVID-19 response. This work was not conducted at AHS, within AHS working hours, or with AHS staff. I contributed and conducted this work as an Independent Epidemiologist, as a member of the Observational Health Data Sciences and Informatics (OHDSI) Network. PR reports grants from Innovative Medicines Initiative, grants from Janssen Research and Development, during the conduct of the study. MS reports grants from US National Science Foundation, grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, during the conduct of the study. GH reports grants from US NIH National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work. APU reports grants from Fundacion Alfonso Martin Escudero, grants from Medical Research Council, outside the submitted work. HA reports personal fees from Eli Lilly and Company, outside the submitted work. AS reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. AS is a full time employee of Janssen and shareholder of Johnson & Johnson. GR is a full time employee of Janssen and shareholder of Johnson & Johnson. FD reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. RWP reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. JP reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. JC reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. SD reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc.,, grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research outside the submitted work. HJ reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. BSKH reports grants from Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001), outside the submitted work. KK reports she is an employee of IQVIA. CR reports he is an employee of IQVIA. JS reports other from Janssen R&D, during the conduct of the study; other from Janssen R&D, outside the submitted work; and JS was a full-time employee of Johnson & Johnson, or a subsidiary, at the time the study was conducted. JS owns stock, stock options, and pension rights from the company. RM reports and is employee of Janssen Research and Development. WG is an AbbVie employee. PR reports and is employee of Janssen Research and Development and shareholder of Johnson & Johnson. MS is a full-time employee of Janssen R&D, and a shareholder of Johnson & Johnson. JH reports other from Janssen Research & Development, during the conduct of the study; other from Janssen Research & Development, outside the submitted work; and full time employee of Janssen and shareholder of Johnson & Johnson.Funding StatementThis project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. This work was also supported by the Bio Industrial Strategic Technology Development Program (20001234) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. Personal funding included Versus Arthritis [21605], Medical Research Council Doctoral Training Partnership (MRC-DTP) [MR/K501256/1] (JL); Medical Research Council (MRC) and Fundación Alfonso Martín Escudero (FAME) (APU); Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001) (BSKH); Singapore Ministry of Health's National Medical Research Council (NMRC) Open Fund Large Collaborative Grant (NMRC/OFLCG/001/2017) (SMK); VINCI [VA HSR RES 13-457] (SLD, MEM, KEL); and NIHR Senior Research Fellowship (SRF-2018-11-ST2-004, DPA). No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, Department of Veterans Affairs or the United States Government, NHS or the Department of Health, England.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOpen Science is a guiding principle within OHDSI. As such, we provide unfettered access to all open-source analysis tools employed in this study via https://github.com/OHDSI/, as well as all data and results artefacts that do not include patient-level health information via http://evidence.ohdsi.org/Covid19CharacterizationHospitalization/. Data partners contributing to this study remain custodians of their individual patient-level health information and hold either IRB exemption or approval for participation.